SOHM starts Neutraceutical manufacturing facility in India
SOHM takes steps to build momentum
BUENA PARK, CA– (01/18/2012) – SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced its Nutraceutical plant have been operational and has commenced commercial production since last month.
Mr. Shailesh Shah, President and CEO said that he is very pleased to announce that last month SOHM’s in-house neutraceutical plant commenced its commercial production of neutraceutical product lines, including Diorac, a unique probiotic anti–diarrheal product. The in house manufacturing plant helps to extend SOHM’s core competence to include neutraceutical at a right time when the United States Food & Drug Administration and the Indian Food & Drug Administration are simplifying regulations in regard to neutraceutical deliverables. We believe these changes and adjustments to the regulations will allow SOHM to more quickly and effectively reach millions of consumers more cost effectively.
Mr. Shah added that SOHM’s new plant, which is located near the company’s India headquarters in Ahmedabad, is in compliance with all Dietary Supplement Health and Education Guidelines. Furthermore the company has received an endorsement and necessary regulatory compliances with local authority as well as with the Indian Food & Drug Administration and Food Standards Authority of India.
As the medicine moves away from palliative and diagnostic paradigm into curative and proactive regiments, neutraceuticals increasingly are seen as a core component in healthy lifestyle management worldwide. To that end SOHM’s organizational competencies will increasingly be deemed to meet growing and evolving market opportunities in the neutraceutical segment, Mr. Shailesh Shah added.
Finally Mr. Shah said in his message that with the commencement of production at the neutraceutical facility, SOHM has reached two milestones. First, SOHM’s pipeline of new and innovative products is now guaranteed. Secondly, when combined with SOHM’s dermatology and generic pharmaceutical operations, the company will be able to expand and enhance distribution channels that will add to revenues and profitability in 2012.
About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com
Safe Harbor Statement
This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
For more information, please contact
516-662-9461 / 714-522-6700